Gilead Sciences Management Discusses Q1 2012 Results - Earnings Call Transcript Seeking Alpha As a final R&D highlight, 3 Phase III studies will be initiated in patients with relapsed or refractory chronic lymphocytic leukemia, or CLL, which is 1101 in combination with rituximab, with bendamustine/rituximab or with ofatumumab. |
